NEWTOWN, Pa.--(BUSINESS WIRE)--CollaGenex Pharmaceuticals, Inc. (NASDAQ:CGPI) today announced that it has initiated enrollment in a 40 mg cohort in its Phase II double-blinded, placebo-controlled, dose-finding clinical trial to determine the appropriate dose for Phase III testing of incyclinide in the treatment of acne. The 40 mg cohort will enroll 100 patients with moderate-to-severe acne at 13 investigational centers across the United States. The placebo-controlled study will evaluate a daily 40 mg dose of incyclinide over a 12 week period.
